nd-t2d-oad-selector

name

nd-t2d-oad-selector

description

Select oral and injectable glucose-lowering agents for a newly diagnosed patient with type 2 diabetes using a compelling-indication hierarchy (heart failure → ASCVD → DKD → obesity) followed by glucose-pattern matching. Incorporates modern GLP-1 receptor agonists — Ozempic (semaglutide SC, T2D), Mounjaro (tirzepatide), and Wegovy/Noveltreat (semaglutide 2.4 mg, obesity). Use when a clinician asks "what drug to start for newly diagnosed T2D", "which OAD to use", "first-line diabetes medication", "SGLT2i vs GLP-1 in new T2D", or presents a newly diagnosed T2D patient needing a personalised medication plan.

OAD Selection — Newly Diagnosed Type 2 Diabetes

Confirm Eligibility First

This tool is for newly diagnosed, non-insulin-requiring T2DM.
Stop here and initiate insulin instead if any of the following apply:

• HbA1c ≥10%
• Any glucose >400 mg/dL
• FBS >200 AND PP2BS ≥300 mg/dL
• Osmotic symptoms (polyuria, polydipsia, weight loss) or ketosis
• GAD antibody positive, OR random C-peptide <0.6 ng/mL with glucose 70–300 mg/dL

Also excluded: pregnancy, age <18, glucocorticoid-induced hyperglycaemia, eGFR <30.

---

Step 1 — Metformin (Universal First Line)

Tab Metformin SR/ER 1 g OD after breakfast

Skip only if: eGFR <30.

Always co-prescribe Methylcobalamin 1000 mcg OD after lunch with metformin.

Expected HbA1c reduction: ~0.8%

---

Step 2 — Compelling Indication Hierarchy

Work through A → D in order. Stop at the first that applies and add the indicated drug.

---

A. Heart Failure

→ Add an SGLT2 inhibitor (proven HF mortality benefit)

Drug	Dose	Trial
Empagliflozin	25 mg OD morning	EMPEROR-Reduced/Preserved
Dapagliflozin	10 mg OD morning	DAPA-HF

---

B. Established ASCVD or High CV Risk

High CV risk = age >55 with ≥2 of: hypertension, overweight/obesity, smoking, LDL ≥100 mg/dL, UACR >30 mg/g

If open to injectable → GLP-1 RA first (proven CV benefit):

Drug	Starting dose	Titration	Max	Trial
Ozempic (semaglutide SC)	0.25 mg SC weekly × 4 wk	→ 0.5 mg × 4 wk	→ 1 mg weekly	SUSTAIN-6
Dulaglutide	0.75 mg SC weekly	Fixed	1.5 mg weekly	REWIND

If not open to injectable → SGLT2 inhibitor:

• Empagliflozin 25 mg OD or Dapagliflozin 10 mg OD

If both GLP-1 RA and SGLT2i contraindicated:

• Pioglitazone 15 mg OD evening (PROACTIVE — CV benefit signal in T2D)
• Skip if: heart failure, BMI >27, macular oedema, retinopathy not assessed

---

C. Diabetic Kidney Disease (eGFR <60 or UACR >30 mg/g)

→ SGLT2 inhibitor first (proven renal benefit):

• Dapagliflozin 10 mg OD (DAPA-CKD)
• Empagliflozin 10 mg OD (EMPA-KIDNEY)

If SGLT2i contraindicated:

• Ozempic (semaglutide SC) 0.25 → 0.5 → 1 mg SC weekly (FLOW trial — renal benefit)

---

D. Obesity (BMI ≥30, or BMI ≥27 with ≥1 comorbidity)

Rank by degree of weight loss needed and injectable preference:

Choice	Drug	Starting dose	Titration to maintenance
1st — best glucose + weight	Mounjaro (tirzepatide)	2.5 mg SC weekly	↑ 2.5 mg every ≥4 wk → max 15 mg
2nd — strong weight + glucose	Wegovy / Noveltreat (semaglutide 2.4 mg)	0.25 mg SC weekly	→ 0.5 → 1 → 1.7 → 2.4 mg (every 4 wk)
3rd — not open to injectable	Dapagliflozin 10 mg or Canagliflozin 300 mg OD	—	—

12-week continuation rule (Wegovy/Noveltreat): reassess at week 12 on maintenance dose. Discontinue if no meaningful BMI improvement.

Mounjaro 2.5 mg note: initiation dose only — not for glycaemic control. First therapeutic dose is 5 mg.

---

Step 3 — Still Above HbA1c Target? Match the Glucose Pattern

Calculate: Delta = PP2BS − FBS (mg/dL)

Delta >60 → Post-meal predominant

Preference	Drug	Dose
Open to multiple pills	Acarbose	50 mg TDS immediately before meals
Not open to multiple pills	Sitagliptin	100 mg OD after breakfast
AGI contraindicated + open to pills	Repaglinide	0.5 mg TDS immediately before meals

⚠️ Do NOT add a DPP-IV inhibitor if already on a GLP-1 RA — redundant mechanisms, no additive benefit.

⚠️ Saxagliptin + heart failure — avoid. Use Sitagliptin instead.

Alpha-glucosidase inhibitors (acarbose) contraindicated if eGFR <25.

Delta ≤60 → Fasting predominant

Drug	Dose	Note
Gliclazide XR (preferred)	60 mg OD, 30 min after breakfast	Lower hypo risk than glimiperide
Glimiperide	1 mg OD, 30 min after breakfast	Alternative

Sulphonylurea contraindicated if: eGFR <15, moderate-to-severe frailty

If SU contraindicated → Pioglitazone 15 mg OD evening (if not already given)

If pioglitazone also contraindicated → Add Basal Insulin:

• Degludec at 10 pm (flexible timing — preferred for shift workers)
• Glargine at 10 pm (fixed timing)
• NPH at 10 pm (budget)

Starting dose: (FBS − 50) ÷ 10 units

---

Step 4 — Neuropathy Add-ons

All patients on metformin → Methylcobalamin 1000 mcg OD (already covered in Step 1).

If painful diabetic peripheral neuropathy is present, add:

• Pregabalin SR 75 mg at 7–8 pm (1–2 h before bedtime)
• Plus, if no ASCVD + BMI normal: Duloxetine 20 mg at bedtime (titrate to 60–120 mg)
• If ASCVD present or BMI >30: Alpha Lipoic Acid 600 mg OD after lunch (use instead of Duloxetine)

---

GLP-1 RA Contraindications (all agents)

• Personal or family history of MTC or MEN-2
• Pancreatitis history (absolute for Noveltreat; strong caution for Ozempic/Mounjaro)
• Severe gastroparesis
• BMI <19 (underweight)
• Pregnancy
• Do not combine with another GLP-1 RA or DPP-IV inhibitor

SGLT2i Contraindications

• eGFR <25
• Ketosis or osmotic symptoms at presentation
• Active genitourinary infection
• BMI <19
• Severe frailty

---

Key Drug Interactions

Combination	Action
GLP-1 RA + sulphonylurea	Reduce SU dose at initiation → glp1-insulin-su-dose-reduction
GLP-1 RA + basal insulin	Reduce insulin by ~20% at initiation
Mounjaro + oral contraceptive	Non-oral or barrier contraception for 4 wk after each dose step → glp1-oral-contraceptive-interaction
DPP-IV + GLP-1 RA	Avoid — stop DPP-IV when adding GLP-1 RA

---

Clinical Guardrails

• Ozempic vs Wegovy/Noveltreat — same molecule (semaglutide), different indication and max dose. Ozempic = T2D glycaemic control, max 1 mg weekly. Wegovy/Noveltreat = obesity, max 2.4 mg weekly. Never co-prescribe.
• Mounjaro 2.5 mg = tolerability dose, not a therapeutic dose. Expect glycaemic benefit from 5 mg onwards.
• Retinopathy + pioglitazone — always assess retinal status before prescribing; can worsen macular oedema.
• Perioperative GLP-1 RA — hold before procedures under GA/sedation. See glp1-perioperative-aspiration.

---

Cross-Reference Skills

Need	Skill
GI side-effect management	glp1-gi-ae-symptom-advisor, glp1-dose-escalation-troubleshooter
Pancreatobiliary monitoring	glp1-pancreatobiliary-risk-monitor
Perioperative decisions	glp1-perioperative-aspiration
SU/insulin dose reduction	glp1-insulin-su-dose-reduction
Mounjaro full prescribing	mounjaro-prescribing-guide
Wegovy/Noveltreat prescribing	wegovy-prescribing-guide, noveltreat-prescribing-guide
DKD staging	nd-t2d-dkd-classifier (coming)
HbA1c target	nd-t2d-hba1c-target (coming)

---

Source

Diabetology.co.in Newly Diagnosed T2DM Algorithm (Lakhani O). Evidence base: ADA Standards of Care 2024; EMPA-REG OUTCOME, EMPEROR; DAPA-HF, DAPA-CKD; EMPA-KIDNEY; SUSTAIN-6; FLOW; REWIND; SURPASS 1–5; STEP 1–4; SURMOUNT 1–4.